Captor Therapeutics Spolka Akcyjna

Warsaw Stock Exchange CTX.WA

Captor Therapeutics Spolka Akcyjna Price to Sales Ratio (P/S) on January 14, 2025: 14.69

Captor Therapeutics Spolka Akcyjna Price to Sales Ratio (P/S) is 14.69 on January 14, 2025, a -57.06% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Captor Therapeutics Spolka Akcyjna 52-week high Price to Sales Ratio (P/S) is 34.21 on January 19, 2024, which is 132.91% above the current Price to Sales Ratio (P/S).
Captor Therapeutics Spolka Akcyjna 52-week low Price to Sales Ratio (P/S) is 14.18 on December 23, 2024, which is -3.44% below the current Price to Sales Ratio (P/S).
Captor Therapeutics Spolka Akcyjna average Price to Sales Ratio (P/S) for the last 52 weeks is 25.64.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Warsaw Stock Exchange: CTX.WA

Captor Therapeutics Spolka Akcyjna

CEO	Dr. Thomas Shepherd Ph.D.
IPO Date	April 1, 2021
Location	Poland
Headquarters	ul. Dunska 11
Employees	105
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.

Key trends

Past 5 years